Cargando…
Procalcitonin and mortality in status epilepticus: an observational cohort study
INTRODUCTION: Acute-phase proteins, such as procalcitonin (PCT), C-reactive protein (CRP) and albumin, may relate with course and outcome in status epilepticus (SE), as seizures bring about inflammation, changes of cytokine levels and blood–brain barrier breakdown. We aimed to determine the predicti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598971/ https://www.ncbi.nlm.nih.gov/pubmed/26450065 http://dx.doi.org/10.1186/s13054-015-1072-9 |
_version_ | 1782394165378678784 |
---|---|
author | Sutter, Raoul Valença, Martina Tschudin-Sutter, Sarah Rüegg, Stephan Marsch, Stephan |
author_facet | Sutter, Raoul Valença, Martina Tschudin-Sutter, Sarah Rüegg, Stephan Marsch, Stephan |
author_sort | Sutter, Raoul |
collection | PubMed |
description | INTRODUCTION: Acute-phase proteins, such as procalcitonin (PCT), C-reactive protein (CRP) and albumin, may relate with course and outcome in status epilepticus (SE), as seizures bring about inflammation, changes of cytokine levels and blood–brain barrier breakdown. We aimed to determine the predictive value of serum levels of PCT at SE onset for the emergence of infections and unfavorable outcome in adult patients with SE. Furthermore, we sought to compare the predictive value of PCT, CRP and albumin for death. METHODS: This observational cohort study was performed in the intensive care units of the University Hospital Basel (Switzerland), a university-affiliated tertiary care center. Adult patients with SE admitted from 2005 to 2012 were included. Serum levels of PCT, CRP and albumin were assessed at SE onset. Unfavorable outcome (i.e., death and a Glasgow Outcome Score of 1 to 3) during hospital stay and mortality after 30 days were considered the primary and infections as the secondary outcome measures. RESULTS: In 91 SE patients, mortality was 23.1 % during hospital stay and at 30-days follow-up. Infections emerged in 30.8 % of patients. In the multivariable analysis, PCT predicted unfavorable outcome independently from possible confounders such as acute etiology, infections during SE, the Charlson Comorbidity Index, and the Status Epilepticus Severity Score (hazard ratio 1.44 per every increasing ug/L, 95 % confidence interval 1.11-1.87). Additional multivariable analysis including serum levels of PCT, CRP and albumin revealed PCT as the only biomarker independently associated with an increased hazard for unfavorable outcome. PCT levels at SE onset were not related to infections during SE. CONCLUSIONS: Serum PCT levels measured at SE onset are independently associated with unfavorable outcome but do not predict the emergence of infections during SE. Procalcitonin may increase the predictive value of clinical scoring systems allowing for rapid risk stratification early in the course of SE. |
format | Online Article Text |
id | pubmed-4598971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45989712015-10-09 Procalcitonin and mortality in status epilepticus: an observational cohort study Sutter, Raoul Valença, Martina Tschudin-Sutter, Sarah Rüegg, Stephan Marsch, Stephan Crit Care Research INTRODUCTION: Acute-phase proteins, such as procalcitonin (PCT), C-reactive protein (CRP) and albumin, may relate with course and outcome in status epilepticus (SE), as seizures bring about inflammation, changes of cytokine levels and blood–brain barrier breakdown. We aimed to determine the predictive value of serum levels of PCT at SE onset for the emergence of infections and unfavorable outcome in adult patients with SE. Furthermore, we sought to compare the predictive value of PCT, CRP and albumin for death. METHODS: This observational cohort study was performed in the intensive care units of the University Hospital Basel (Switzerland), a university-affiliated tertiary care center. Adult patients with SE admitted from 2005 to 2012 were included. Serum levels of PCT, CRP and albumin were assessed at SE onset. Unfavorable outcome (i.e., death and a Glasgow Outcome Score of 1 to 3) during hospital stay and mortality after 30 days were considered the primary and infections as the secondary outcome measures. RESULTS: In 91 SE patients, mortality was 23.1 % during hospital stay and at 30-days follow-up. Infections emerged in 30.8 % of patients. In the multivariable analysis, PCT predicted unfavorable outcome independently from possible confounders such as acute etiology, infections during SE, the Charlson Comorbidity Index, and the Status Epilepticus Severity Score (hazard ratio 1.44 per every increasing ug/L, 95 % confidence interval 1.11-1.87). Additional multivariable analysis including serum levels of PCT, CRP and albumin revealed PCT as the only biomarker independently associated with an increased hazard for unfavorable outcome. PCT levels at SE onset were not related to infections during SE. CONCLUSIONS: Serum PCT levels measured at SE onset are independently associated with unfavorable outcome but do not predict the emergence of infections during SE. Procalcitonin may increase the predictive value of clinical scoring systems allowing for rapid risk stratification early in the course of SE. BioMed Central 2015-10-09 2015 /pmc/articles/PMC4598971/ /pubmed/26450065 http://dx.doi.org/10.1186/s13054-015-1072-9 Text en © Sutter et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sutter, Raoul Valença, Martina Tschudin-Sutter, Sarah Rüegg, Stephan Marsch, Stephan Procalcitonin and mortality in status epilepticus: an observational cohort study |
title | Procalcitonin and mortality in status epilepticus: an observational cohort study |
title_full | Procalcitonin and mortality in status epilepticus: an observational cohort study |
title_fullStr | Procalcitonin and mortality in status epilepticus: an observational cohort study |
title_full_unstemmed | Procalcitonin and mortality in status epilepticus: an observational cohort study |
title_short | Procalcitonin and mortality in status epilepticus: an observational cohort study |
title_sort | procalcitonin and mortality in status epilepticus: an observational cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598971/ https://www.ncbi.nlm.nih.gov/pubmed/26450065 http://dx.doi.org/10.1186/s13054-015-1072-9 |
work_keys_str_mv | AT sutterraoul procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy AT valencamartina procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy AT tschudinsuttersarah procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy AT rueggstephan procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy AT marschstephan procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy |